RU2008128870A - IMMUNITIES NUCLEIC ACIDS - Google Patents
IMMUNITIES NUCLEIC ACIDS Download PDFInfo
- Publication number
- RU2008128870A RU2008128870A RU2008128870/13A RU2008128870A RU2008128870A RU 2008128870 A RU2008128870 A RU 2008128870A RU 2008128870/13 A RU2008128870/13 A RU 2008128870/13A RU 2008128870 A RU2008128870 A RU 2008128870A RU 2008128870 A RU2008128870 A RU 2008128870A
- Authority
- RU
- Russia
- Prior art keywords
- specified
- oligonucleotide
- subject
- administered
- amount effective
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Иммуностимулирующий олигонуклеотид, содержащий 5'T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*T 3' (SEQ ID NO. 313). ! 2. Способ модуляции иммунного ответа, предусматривающий введение субъекту олигонуклеотида по п.1, в количестве эффективном для модуляции иммунного ответа. ! 3. Способ по п.2, где указанный олигонуклеотид вводят указанному субъекту для лечения астмы или аллергии. ! 4. Способ по п.2, где указанной субъект страдает злокачественной опухолью, инфекционным заболеванием или аутоиммунным заболеванием. ! 5. Способ по п.2, который дополнительно предусматривает проведение лечения указанного субъекта в соответствии с такой методикой, как хирургическое вмешательство, лучевая терапия или медикаментозная терапия. ! 6. Способ по п.2, где указанный олигонуклеотид входит в состав лекарственного препарата. ! 7. Способ по п.2, где указанный олигонуклеотид вводят способом, выбранным из группы, состоящей из перорального, интраназального, подъязычного, внутривенного, подкожного, трансмукозального способа введения, введения через дыхательные пути, прямой инъекции и внутрикожного введения. ! 8. Способ по п.2, где указанный олигонуклеотид вводят указанному субъекту в количестве, эффективном для индуцирования экспрессии цитокинов, где цитокины необязательно включают IL-6, TNFα, IFNα, IFNγ и IP-10. ! 9. Способ по п.2, где указанный олигонуклеотид вводят указанному субъекту в количестве, эффективном для переключения иммунного ответа с Th2-ответа на Th1-ответ.1. Immunostimulatory oligonucleotide containing 5'T * C_G * T * C_G * T * T * T * T * G * A * C_G * T * T * T * T * G * T * C_G * T * T 3 '( SEQ ID NO. 313). ! 2. A method for modulating an immune response, comprising administering to a subject the oligonucleotide of claim 1, in an amount effective to modulate the immune response. ! 3. The method according to claim 2, where the specified oligonucleotide is administered to the specified subject for the treatment of asthma or allergies. ! 4. The method according to claim 2, where the specified subject suffers from a malignant tumor, infectious disease or autoimmune disease. ! 5. The method according to claim 2, which additionally provides for the treatment of the specified subject in accordance with a technique such as surgery, radiation therapy or drug therapy. ! 6. The method according to claim 2, where the specified oligonucleotide is part of the drug. ! 7. The method according to claim 2, where the specified oligonucleotide is administered by a method selected from the group consisting of oral, intranasal, sublingual, intravenous, subcutaneous, transmucosal administration, administration through the respiratory tract, direct injection and intradermal administration. ! 8. The method according to claim 2, where the specified oligonucleotide is administered to the specified subject in an amount effective to induce the expression of cytokines, where the cytokines optionally include IL-6, TNFα, IFNα, IFNγ and IP-10. ! 9. The method according to claim 2, where the specified oligonucleotide is administered to the specified subject in an amount effective to switch the immune response from the Th2 response to the Th1 response.
Claims (9)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40447902P | 2002-08-19 | 2002-08-19 | |
US40482002P | 2002-08-19 | 2002-08-19 | |
US60/404,820 | 2002-08-19 | ||
US60/404,479 | 2002-08-19 | ||
US60/429,701 | 2002-11-27 | ||
US44737703P | 2003-02-14 | 2003-02-14 | |
US60/447,377 | 2003-02-14 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005107708/04A Division RU2338750C2 (en) | 2002-08-19 | 2003-08-19 | IMMUNOSTIMULATING PHOSPHOROTHIOATE CpG-OLIGONUCLEOTIDES, CONTAINING PHOSPHODIESTER LINKS, METHOD OF IMMUNOMODULATION, METHOD OF IMMUNE RESPONSE STIMULATION |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2008128870A true RU2008128870A (en) | 2010-01-20 |
Family
ID=36049798
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005107708/04A RU2338750C2 (en) | 2002-08-19 | 2003-08-19 | IMMUNOSTIMULATING PHOSPHOROTHIOATE CpG-OLIGONUCLEOTIDES, CONTAINING PHOSPHODIESTER LINKS, METHOD OF IMMUNOMODULATION, METHOD OF IMMUNE RESPONSE STIMULATION |
RU2008128870/13A RU2008128870A (en) | 2002-08-19 | 2008-07-14 | IMMUNITIES NUCLEIC ACIDS |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005107708/04A RU2338750C2 (en) | 2002-08-19 | 2003-08-19 | IMMUNOSTIMULATING PHOSPHOROTHIOATE CpG-OLIGONUCLEOTIDES, CONTAINING PHOSPHODIESTER LINKS, METHOD OF IMMUNOMODULATION, METHOD OF IMMUNE RESPONSE STIMULATION |
Country Status (1)
Country | Link |
---|---|
RU (2) | RU2338750C2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
KR102230325B1 (en) * | 2015-09-30 | 2021-03-19 | 시오노기 앤드 컴파니, 리미티드 | Nucleic acid derivatives with immune activation activity |
RU2697527C1 (en) * | 2018-06-06 | 2019-08-15 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук" (ФГУ ФИЦ Биотехнологии РАН) | Immunoadjuvant composition for vaccines for infectious agents of viral and bacterial nature |
-
2003
- 2003-08-19 RU RU2005107708/04A patent/RU2338750C2/en active
-
2008
- 2008-07-14 RU RU2008128870/13A patent/RU2008128870A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2338750C2 (en) | 2008-11-20 |
RU2005107708A (en) | 2006-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ547776A (en) | Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein | |
RU2007118681A (en) | SEMI-SOFT IMMUNITIES MULATING S-CLASS OLIGONUCLEOTIDES | |
EP1728863A3 (en) | C-class oligonucleotide analogs with enhanced immunostimulatory potency | |
NZ541013A (en) | A composition comprising a polypeptide comprising SEQ ID NO:577 for use in treating chlamydial infection | |
JP2004513622A5 (en) | ||
AU4951196A (en) | Vaccines for plague | |
IL186993A (en) | Attenuated microorganisms for the treatment of infection | |
DK0784483T3 (en) | Composition containing a recombinant virus expressing an antigen and a recombinant virus expressing an immune stimulus | |
DE60142683D1 (en) | IMMUNOSTIMULATING POLYNUCLEOTIDE SEQUENCES FOR USE IN THE PREVENTION AND TREATMENT OF VIRAL DISEASES | |
EP0816499A3 (en) | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma | |
HUP0500238A2 (en) | Interleukin-12 as a veterinary vaccine adjuvant | |
ATE228016T1 (en) | LIVE VACCINES FOR THE TREATMENT OF TUMOR DISEASES | |
RU2008128870A (en) | IMMUNITIES NUCLEIC ACIDS | |
Operschall et al. | Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice | |
MXPA02005506A (en) | Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens. | |
Osorio et al. | Immune responses to hepatitis B surface antigen following epidermal powder immunization | |
CA2405458A1 (en) | Herpes viruses for immune modulation | |
DE60313437D1 (en) | MHC CLASS I PEPTIDEPITOPES OF HUMAN TUMOR ASSOCIATED ANTIGEN 5T4 | |
EA200301125A1 (en) | VACCINES INCLUDING AS AN ADJUVANT INTERFERON TYPE I AND RELATED METHODS | |
AU2021374649A9 (en) | Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine | |
CN1438238A (en) | Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof | |
RU2004104335A (en) | BIOLOGICALLY ACTIVE PEPTIDES | |
CN102038951B (en) | Nucleic acid vaccine adjuvant designed based on MCP-1 and construction method thereof | |
Nishitani et al. | Cytokine gene therapy for cancer with naked DNA | |
CN102000330B (en) | Nucleic acid vaccine adjuvant and construction method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20111010 |